Nexsen delays StrepSure FDA submission by one quarter

• Nexsen halted the clinical evaluation of its StrepSure diagnostic device to implement technical enhancements.
• Executives expect the Q4 2026 United States regulatory submission to be delayed by a quarter, with shares remaining unchanged at $0.16.
• Nexsen stated this early intervention strengthens the product using real-world evidence before the business commits substantial capital.

Nexsen (ASX:NXN) paused its StrepSure clinical trial for product enhancements, which the company expects will delay regulatory submission by one quarter.

The decision follows a predefined interim data review from a Melbourne study, which immediately halted further patient enrolment.

The company stated the next development phase focuses on diagnostic signal enhancement rather than a fundamental device redesign.

Managing Director Mark Muzzin commented, "Making this decision now avoids committing substantially more capital to the current configuration and reduces the risk of having to repeat clinical and regulatory work at a later, more expensive stage."

Executives expect the targeted Q4 2026 submission to shift by three months without requiring material additional development expenditure. The company stated its Asia-Pacific operations continue as planned.

Following the announcement, the Nexsen share price was unchanged at $0.16.

The rapid test screens for Group B Streptococcus in women during labour to provide instant maternal health diagnostics.